All In Biotech

Drug Trial Radar · NCT02524288

Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring in Women at Risk for Pregnancy (MK-8342B-061)

A Phase 3, Single Arm, Clinical Trial to Study the Contraceptive Efficacy and Safety of the MK-8342B (Etonogestrel + 17β-Estradiol) Vaginal Ring in Healthy Women 18 Years of Age and Older, At Risk for Pregnancy

Last checked: Nov 20, 2026Latest source record: May 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,941

Actual

Start

Aug 31, 2015

Primary completion

Sep 16, 2016

Study completion Sep 16, 2016

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Aug 14, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the contraceptive efficacy of the Etonogestrel (ENG) + 17β-Estradiol (E2) vaginal ring in women between 18 and 35 years of age based on the number of in-treatment pregnancies as expressed by the Pearl Index (PI). The study will also assess the safety and tolerability of the ENG-E2 vaginal ring.

Conditions

  • Contraception

Interventions

  • ENG-E2 125 μg/300 μg vaginal ringDrug

    Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of In-Treatment Pregnancies Per 100 Woman-Years of Exposure in Participants 18-35 Years of Age (Pearl Index)Time frame: Up to 1 year (13 28-day cycles)
  2. Number of Participants With One or More Adverse Events (AEs)Time frame: From insertion of the first vaginal ring up to and including 14 days after removal of the last vaginal ring (up to approximately 1 year)
  3. Number of Participants Who Discontinued Treatment Due to an AETime frame: From insertion of the first vaginal ring up to and including 14 days after removal of the last vaginal ring (up to approximately 1 year)
  4. Number of Participants With One or More Drug-related AEsTime frame: From insertion of the first vaginal ring up to and including 14 days after removal of the last vaginal ring (up to approximately 1 year)
  5. Number of Participants Who Discontinued Treatment Due to a Drug-related AETime frame: From insertion of the first vaginal ring up to and including 14 days after removal of the last vaginal ring (up to approximately 1 year)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.